← Eichor
Study identifier: NCT07228442 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma

Condition: Locally Advanced Cutaneous Squamous Cell Carcinoma  ·  Sponsor: Philogen S.p.A.

PhasePhase 2
Planned participants92
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Open-label, single-arm, multicenter study in patients with locally advanced, histologically confirmed Cutaneous Squamous Cell Carcinoma (LacSCC) amenable to intratumoral injection, who have progressed on or are intolerant to Immune Checkpoint Inhibitor (ICI). The primary objective of the study is to evaluate the activity of intratumoral L19IL2/L19TNF, while the secondary objective is to assess the safety and efficacy. The patients will receive multiple intratumoral administrations of combined L19IL2 and L19TNF to all injectable cutaneous and subcutaneous lesions once weekly for up to 4 weeks: for those who have a partial response or stable disease as their best response, a second 4-week course L19IL2/L19TNF of four weekly injections may be administered as per treating physician judgement. Patients will be followed for a maximum of 160 weeks after beginning of treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Lisa Nadal  ·  +3905771526723  ·  lisa.nadal@philogen.com

Concetta Aulicino  ·  +39057717816  ·  regulatory@philogen.com

Always discuss trial participation with your own doctor first.

Locations (19)

UC Irvine Health- Chao Family Comprehensive Cancer CenterOrange, California, United StatesRecruiting
Winship Cancer Institute, Emory UniversityAtlanta, Georgia, United StatesRecruiting
Dana-Farber Cancer InstituteBoston, Massachusetts, United StatesRecruiting
Duke University Medical CenterDurham, North Carolina, United StatesRecruiting
The Ohio State University Wexner Medical Center Clinical LaboratoriesColumbus, Ohio, United StatesNot Yet Recruiting
The University of Texas MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting
Universitaetsklinikum AugsburgAugsburg, GermanyRecruiting
Charite Universitaetsmedizin Berlin KöRBerlin, GermanyRecruiting
Universitaetsklinikum Essen AöREssen, GermanyRecruiting
Universitaetsklinikum Halle (Saale) AöRHalle, GermanyRecruiting
Universitaetsklinikum Heidelberg AöRHeidelberg, GermanyRecruiting
Universitaetsklinikum Schleswig-Holstein AöRKiel, GermanyRecruiting

+ 7 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07228442